Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

GSK is laying out €250 million to bolster vaccine manufacturing with a new facility to help make free-dried shots, including for shingles and RSV.